End-Organ Protection in Patients with Hypertension
- 1 May 2011
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 71 (8) , 1003-1017
Abstract
The renin-angiotensin system (RAS) plays a key role in a number of pathophysiological mechanisms that are involved in the development and progression of cardiovascular and renal disease. For these reasons, pharmacological antagonism of this system, particularly the blockade of formation or the receptor antagonism of angiotensin II, has been demonstrated to be an effective and safe strategy to reduce the burden of cardiovascular disease. Among different drug classes, angiotensin II type I receptor antagonists (angiotensin receptor blockers [ARBs]) have provided an excellent alternative to ACE inhibitors, representing a more selective and a better tolerated pharmacological approach to interfere with the RAS. Results derived from large, international, randomized clinical trials have consistently indicated that ARB-based therapeutic strategies may effectively provide cardiovascular and renal disease prevention and protection in different clinical conditions across the entire cardiovascular continuum. This article reviews the pathophysiological rationale of RAS involvement in the pathogenesis of renal diseases, focusing on the beneficial effects provided by ARBs in terms of renal protectionKeywords
This publication has 65 references indexed in Scilit:
- Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trialsBMJ, 2008
- Effects of Losartan in Women With Hypertension and Left Ventricular HypertrophyHypertension, 2008
- Comparison of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Essential HypertensionDrugs, 2008
- Global burden of hypertension: analysis of worldwide dataThe Lancet, 2005
- Treating Hypertension with Angiotensin II Receptor BlockersHigh Blood Pressure & Cardiovascular Prevention, 2005
- Blood pressure is insufficiently controlled in European patients with established coronary heart diseaseJournal Of Hypertension, 2003
- Biochemistry and Pharmacology of the Renin-Angiotensin SystemDrugs, 1990
- Importance of the Renin-Angiotensin-Aldosterone System (RAS) in the Physiology and Pathology of HypertensionDrugs, 1990
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987
- The Renin-Angiotensin System in the Control of Systemic Arterial PressureDrugs, 1985